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Abstract
Introduction: Both beta-amyloid (Ab) deposition and decline in white matter integrity,
are brain alterations observed in Alzheimer’s disease (AD) and start to occur by the
fourth and fifth decades. However, the association between both brain alterations in
asymptomatic subjects is unclear.
Methods: Amyloid positron emission tomography (PET) and diffusion tensor imaging
(DTI) were obtained in 282 cognitively normal subjects (age 30-89 years). We assessed
the interaction of age by abnormal amyloid PET status (Florbetapir F-18 PET>1.2 stan-
dard uptake value ratio [SUVR]) on regionalmeandiffusivity (MD) and globalwhitemat-
ter hyperintensity (WMH) volume, controlled for sex, education, and hypertension.
Results: Subjects with abnormal amyloid PET (n = 87) showed stronger age-related
increase in global WMH and regional MD, particularly within the posterior parietal
regions of the white matter.
Discussion: Sporadic A𝛽 deposition is associated with white matter alterations in AD
predilection areas in an age-dependent manner in cognitively normal individuals.
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1 INTRODUCTION
White matter alterations are common in Alzheimer’s disease (AD).1
Although cortical neurodegeneration is a core feature of AD, several
lines of research suggest that white matter impairment is part of the
pathological cascade in AD.2-5 Brain autopsy studies showed partial
loss of axons, reduced myelin, and increased astrogliosis in the white
matter in patients with pathological diagnosis of AD.2,6 White matter
hyperintensity volume, a gross radiological marker of white matter
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alterations, is increased in autosomal dominant AD, that is, genetically
caused AD with an early onset of dementia symptoms.7 These results
suggest that pathological white matter changes are not merely due to
aging but constitute a significant feature of AD. Studies using diffu-
sion tensor imaging (DTI) showed that microstructural white matter
alterations occur in a region-specific manner,8,9 predominantly within
posterior parietal white matter in very mild AD.4,10-12 In autosomal
dominant AD, we previously found that DTI-assessed mean diffusivity
(MD) was increased predominantly in posterior parietal white matter
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5-10 years before symptom onset.13 Together these results suggest
that white matter alterations occur in circumscribed brain regions at
an early pre-symptomatic stage of AD.14
The deposition of cortical amyloid 𝛽 (A𝛽; henceforth we refer only
to cortical A𝛽) precedes the onset of Alzheimer’s disease (AD) symp-
toms by >20 years,15,16 typically beginning within the fourth or fifth
decade of life.17,18 A𝛽 deposition has been associated previously with
small vessel disease in the form of capillary cortical amyloid angiopa-
thy (CAA) and arteriosclerosis,6,19,20 which may entail white matter
damage.6,21,22 These observations suggest that the A𝛽 deposition
occurring during middle and older age is associated with accelerated
age-related white matter alterations, even though the exact mecha-
nisms remain unclear. Results from lifespan diffusion tensor imaging
(DTI) studies suggest maturation of fiber tracts to continue until the
fourth decade of life,23 followed by decline in white matter integrity at
a higher age.23–25 Few studies, however, have assessed the association
between early accrual of A𝛽 deposition and white matter decline in
asymptomatic middle-aged and older adults.4,26-29 In elderly cogni-
tively normal subjects, higher A𝛽 deposition (as assessed by amyloid
PET) was associated with DTI alterations within the splenium30 and
cingulum bundle.31 In late middle-aged cognitively normal subjects,
abnormal levels of A𝛽 have only inconsistently been associated with
DTI alterations,12,27,32,33 probably because the small sample size
hampered statistical power.12,32,33 Therefore, the question remains
whether microstructural white matter alterations are associated with
early cerebral amyloid deposition. In addition, there are few studies of
middle-aged adults and it is not clear at what age these associations
can be observed. We addressed these questions using a large sample
of participants from the Dallas Lifespan Brain Study (DLBS), including
282 cognitively normal adults from age 30-89, allowing us to examine
the association between deposition of A𝛽 andwhitematter alterations
across the adult life span. Based on our previous findings of predom-
inantly posterior parietal alterations of MD in autosomal dominant
AD13,13 our primary hypothesis was that A𝛽 deposition is associated
with a higher age-related increase of MD, particularly in posterior
parietal and long-projecting frontoparietal fiber tracts.
2 METHODS
2.1 Subjects
We studied 294 cognitively normal subjects from the or DLBS. Inclu-
sion criteria required the individuals to be right-handed, native English
speakers, aMiniMental State Examination (MMSE) score of≥26; avail-
ableDTI, T1MRI, and Florbetapir F-18 PET scans aswell as completion
of a cognitive test battery. The age rangewas between 30 and 89 years.
Quality control prior and after pre-processing of T1 and DTI images
resulted in the exclusion of 12 subjects due to anatomical abnormali-
ties (abnormally enlarged ventricles: n = 1; abnormally enlarged sub-
arachnoid spaces: n = 1) or artifacts/noise that prevented a success-
ful pre-processing (DTI: n = 6, T1: n = 4), yielding a total of 282 sub-
jects. Unless otherwise specified for a specific analysis, this was the
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1. Systematic review: White matter alterations including
white matter hyperintensities and microstructural white
matter alterations are part of the pathological brain
changes in Alzheimer’s disease (AD), but may precede
symptom onset by decades. Amyloid 𝛽 (A𝛽), a primary
pathology of AD, starts to occur 20-25 years before
symptom onset. Whether A𝛽 deposition is associated
with white matter alterations in asymptomatic subjects
already duringmiddle and older age is unclear.
2. Interpretation: Our finding in cognitively normal subjects
between 30 and 89 years suggested that increased amy-
loid positron emission tomography (PET) is already asso-
ciated with the posterior parietal regions. These white
matter changes were independent of hypertension and
may thus stem from amyloid angiopathy in the brain.
3. Future directions: The current findings encourage future
longitudinal investigations on the contribution of amyloid
related white matter alterations to the development of
dementia.
final sample used for all statistical analyses. The two cognitive visits
were a median of 3 days apart (interquartile range [IQR] = 5, min = 0,
max= 69).
The MRI was acquired a median of 11 days after the second cog-
nitive visit (IQR = 13, min = −7, max = 132). The PET was acquired a
median of 82 days after the MRI (IQR = 202.2, min = −21, max = 593;
only 19 subjects had their PET taken>1 year after theMRI).
Written informed consent was obtained according to the policy of
the institutional review board of the University of Texas Southwestern
Medical Center and the University of Texas at Dallas.
2.2 Cognitive assessments
The overall cognitive status was assessed with MMSE. Composite
scores of episodic memory and executive function were computed
as described previously.34 Briefly, for episodic memory, the number
of correct items in the immediate and delayed tests of the Hopkins
Verbal Learning Task and the number of items correctly remembered
in the Verbal Recognition Memory task from the Cambridge Neu-
ropsychological Test Automated Battery (CANTAB) were each z-score
transformed. The average z-score across the tests was computed
for each subject to yield the episodic memory composite score. For
executive function, measures of processing speed (number of correct
items on the Digit Symbol and Digit Comparison tasks) and working
memory (number of correct items on the Letter-Number Sequencing
task and sum of perfectly recalled trials on the Operation Span task)
were each z-score transformed. The z-scores averaged across all of
these tests yielded the executive function composite score.
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2.3 Assessment of hypertension
The hypertensive status of the patients in the DLBS has been reported
previously.18 Briefly, an individual was considered hypertensive if
she/he had either a diagnosis of hypertension by her/his physician, or
if the blood pressure, as obtained during the study, exceeded the cri-
terion for stage 1 hypertension (systolic blood pressure >140 mm Hg
or diastolic blood pressure>90mmHg). Blood pressurewasmeasured
twice at eachof two cognitive visits, twice during thePETvisit andonce
during the MRI visit. Measurements were obtained with an automatic
sphygmomanometer (HEM-780; Omron) attached to the left arm of
the participant who was either seated (cognitive visit) or in the supine
position (PET visit). Systolic and diastolic blood pressure values were
averaged across all seven visits.
2.4 MRI acquisition
MRI scans were acquired by a Philips Achieva 3 T MR scanner (Philips
Medical Systems, Best, The Netherlands). The T1-weighted images
were acquired with an magnetization prepared rapid gradient echo
(MPRAGE) sequence with 1 mm isotropic voxel size, repetition time
(TR) = 8.18 ms, echo time (TE) = 3.76 ms, and flip-angle = 12◦.
Diffusion-weightedMRIwas acquired usingwhole-brain T2*-weighted
interleaved echo-planar imaging (EPI) with 2 mm isotropic voxel size,
TR = 4410 ms, TE = 51 ms, flip-angle = 90◦, and 1 mm slice gap. One
b = 0 volume and 30 diffusion directions were recorded with b = 1000
s/mm2. T2–fluid-attenuated inversion recovery (FLAIR) scans were
acquired axially (repetition time = 11,000 ms, echo time = 125 ms, flip
angle= 120◦) with 0.45mm × 0.45mm × 5.96mm voxel size.
2.5 𝜷 Amyloid PET
Amyloid deposition was measured by scanning participants in a
Siemens ECATHRPET Scanner using Florbetapir F-18. The scan began
50 minutes after injection of a 370 MBq (10 mCi) dose of the Flor-
betapir F-18 radiotracer. A two-frame × 5-minute dynamic emission
acquisition was performed, reconstructed using back-projection. The
scans were spatially normalized to a Florbetapir F-18 template in
Montreal Neurological Institute (MNI) (2 mm isotropic resolution),
and a 6 mm full width at half maximum (FWHM) Gaussian filter was
applied. The computation of global Florbetapir F-18 followed a pro-
cedure described previously for Florbetapir F-18 PET scans in the
DLBS study.35 The radiotracer uptake was averaged across voxels
within each of eight predefined cortical regions of interest (ROIs),
including the dorsolateral prefrontal cortex, orbitofrontal cortex, lat-
eral parietal cortex, posterior and anterior cingulate, precuneus, lat-
eral temporal cortex and occipital cortex.34-36 For each subject and
ROI, the average PET values were normalized to the whole cerebel-
lum to compute standard uptake value ratios (SUVR); these PET val-
ues were averaged across the eight ROIs to obtain the global SUVR
score.35
2.6 Amyloid 𝜷 status
Subjects were classified into two groups based on the global SUVR
score, which provided a measure of the magnitude of A𝛽 uptake in the
brain. Amyloid positivity (A𝛽+) was thresholded at a global SUVR≥1.2,
as established previously,35 and participants with a lower global SUVR
score were termed amyloid negative (A𝛽−).
2.7 DTI pre-processing
The diffusion-weighted volumes and the b = 0 reference volume
were pre-processed by a standard procedure implemented in the
ExploreDTI toolbox (http://www.ExploreDTI.com).37 In particular, the
DTI scans were corrected for subject motion and eddy currents, and
the same transformations that were applied to the diffusion-weighted
volumes were also applied to the B-matrix of diffusion directions.38
For each subject, the thus corrected DTI scan was adjusted subse-
quently for susceptibility distortions by nonlinear registration to the
subject’s brain-extracted T1 volume, using the Explore DTI toolbox.39
A particular feature of this procedure is that the deformations can
be restricted to the phase-encoding direction of the DTI scan (ie, the
anterior-posterior direction in our case). Finally, diffusion-tensor esti-
mationbyordinary least-squareswas carriedout to generate fractional
anisotropy (FA as required for tract-based spatial statistics [TBSS], see
next section) andMDmaps for each subject.
2.8 Tract-based spatial statistics
The MD maps were superimposed onto a white matter skeleton
template, using TBSS40 included in the FSL toolbox (https://fsl.fmrib.
ox.ac.uk/fsl/fslwiki). The skeletonized MD maps were normalized to
the FMRIB58 FA template in MNI space, using the spatial normaliza-
tion routine and standard parameters of TBSS.40 Then the obtained
MD maps were multiplied with a conservatively defined binary white
matter skeleton mask adopted from the TBSS toolbox to reduce par-
tial volume effects, excluding the fornix and other regions susceptible
to such effects, as described previously.41 For the extraction of fiber
tract ROI values of MD, the binarized Johns-Hopkins University fiber
tract atlas42 inMNI spacewas superimposed onto each subject’s skele-
tonized MD map and the mean MD was computed for each fiber tract
ROI.
2.9 Whitematter hyperintensitymeasurement
and probability mapping
White matter hyperintensities (as defined by the standards for
reporting vascular changes on neuroimaging (STRIVE) criteria)43 were
segmented based on FLAIRMRI scans, using a semiautomatedmethod
that was described previously.44 (For a more detailed description see
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supplementary methods.) Global white matter hyperintensity (WMH)
volume was computed by summing the voxels classified as WMH and
multiplying the resulting sum by the voxel size of the native FLAIR
scan. The total WMH volume was divided by the total brain volume
to obtain a normalized global WMH volume (henceforth called WMH
ratio). Because WMHs typically have a very skewed distribution, we
applied an inverse-hyperbolic sine transform to the WMH volume
ratio, as reported previously.7
WMHprobabilitymapswere separately computed forA𝛽− andA𝛽+
groups stratified by four age groups in order to display the age-related
distribution ofWMH: (1) 46 to 59 years, (2) 60 to 69 years, (3) 70 to 79
years, and (4) 80 to 89 years. Unlike in the previous analyses, where
the age of the subjects was unrestricted between 30 and 89 years,
for this particular analysis, a higher age limit was chosen as the age
of the youngest A𝛽+ subject (46 years), resulting in the sample size
n = 254 (167 A𝛽−, 87 A𝛽+). Within each group, the spatially normal-
ized and binarizedWMHmapswere concatenated across subjects. For
each voxel, the number of subjects showing a WMH was counted, and
this numberwas divided by the total number of subjects in the group to
obtain the proportion ofWMHoccurrences for each voxel.
2.10 Data analysis
2.10.1 TBSS analysis of the effect of age
and A𝜷 onMD
To test whether any observed association between age and MD was
moderated by the presence of A𝛽 deposition, we conducted TBSS-
based regression analyses including voxel values of MD as the depen-
dent variable and the interaction age by A𝛽 status (A𝛽− vs A𝛽+) as
the main predictor, controlled for age, A𝛽 status, sex, and education.
Statistical significance was determined based on the Randomise Tool-
box of FSL,45 conducting nonparametric permutation inference using
threshold-free cluster enhancement (TFCE; recommended for TBSS
analyses) to correct for family-wise error (FWE).
In order to assess whether some patients had abnormal cognitive
performance, we expressed each patient’s composite score of episodic
memory and executive function in terms of SD) from the group mean.
Composite scores were adjusted by age, gender, and years of educa-
tion as described in,3 using linear regression. The linear regression
equations were:
zadj (i) = zraw (i) −
(
Bage × (age (i) −mean (age)
)
+Bgender × (Gender (i) − Gender0)
+Bedu × (Education (i) −mean (Education))
zraw (i) is the unadjusted composite score for subject (i) and similarly
for zadj (i), age (i), Gender (i) and Education (i). Gender0 represents
the Gender reference value (female) and Bage, Bgender, and Bedu rep-
resent the linear regression coefficients for age, gender, and years of
education, respectively.
We considered subjects with zadj < −1.5 (ie, 1.5 SDs below the
adjusted mean) in either episodic memory or executive function as
potentially not cognitively healthy.
Results showed that in total, 4 of 282 (1A𝛽− and1A𝛽+) were below
the episodic memory threshold only.
2.11 ROI-based analysis of the effect
of age and A𝜷 onMD
We tested the same linear regression models as described earlier for
the TBSS analysis on the interaction age by A𝛽 status onMD, this time
having fiber tract ROI values ofMDas the dependent variables. In addi-
tional linear regression analyses we tested whether any interaction
effect of A𝛽 status x age remained when controlling for hypertension
(note that for one patient the blood pressure measurement was miss-
ing). Because the tract-ROI–based analyses of MD was a secondary
analysis, a significance threshold of P < 0.05 uncorrected for multiple
comparisons was applied. Effect size f2 was computed for the age and
age x A𝛽 status terms.
2.12 Assessing the influence of the APOE genotype
We tested whether the APOE 𝜀4 genotype (𝜀4 carrier vs no 𝜀4 carrier)
was associated with the main predictors, that is, age (through a t test)
and A𝛽 PET status (via chi-square).
In a TBSS analysis, APOE genotype and interaction term APOE
genotype x age were tested as predictors of MD, controlled for age,
gender, and education, using non-parametric permutation inference
using threshold-free cluster enhancement (TFCE; recommended for
TBSS analyses) to correct for family-wise error (FWE), with a corrected
significance threshold of 𝛼 = 0.05.
2.13 Analysis of the effect of age and A𝜷 onWMH
To assess the effect of A𝛽 status on WMH burden, we formulated a
regression model with transformed WMH volume ratio as the depen-
dent variable and the interaction age x A𝛽 status as the main predic-
tor, with the rest of the covariates as per subsequent text. Because the
inverse hyperbolic-sine transformation still resulted in a skewed distri-
bution ofWMHvolume (withmany patients showing few to noWMH),
we used robust linear regression including weighted least squares, as
implemented in the R packageMASS.46
3 RESULTS
3.1 Patients’ characteristics
Patients’ characteristics are displayed in Table 1 for the A𝛽 groups.
A𝛽+ patients were older (t = 6.4, P < 0.001) and had lower executive
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TABLE 1 Characteristics of patients with normal (A𝛽−) and abnormal (A𝛽+) amyloid PET
A𝜷− (n= 195) A𝜷+ (n= 87) P-value
Sex (female) 117 (60%) 56 (64%) P= 0.595
APOE 𝜀4 status (carriers) 36 (20%)
b
20 (25%)
b
P= 0.573
Ethnicity2
White/Caucasian 170 79 P= 0.3143
African American/Black 12 4
Other 11 2
Age in years (mean± SD)/range 60.7± 13.5/30− 88 70.3± 10.8/46− 89 P< 0.001
Years of education (mean± SD) 15.4± 2.2 15.6± 2.3 P= 0.551
Composite episodic memory score (mean± SD) 0.08± 0.82 −0.16± 0.75 P= 0.009
Composite executive function score (mean± SD) 0.10± 0.77 −0.24± 0.77 P< 0.001
Brain volume inmm3 (median± SD; ×106) 1.37± 0.14 1.38± 0.12 P= 0.052
Whitematter volume inmm3 (mean± SD; ×105) 4.97± 0.67 5.01± 0.63 P= 0.001
WMHvolume inmm3 (median± IQR;×10−3) 2.31± 3.5 5.19± 9.92 P< 0.001
WMHvolume ratio (median± IQR;×10−3) 1.71± 2.76 4.06± 7.30 P< 0.001
Blood pressure, systolic, in mmHg (mean± SD) 127.9± 17.4 130.6± 17.3 P= 0.176
Blood pressure, diastolic, in mmHg (mean± SD) 81.3± 10.1 82.0± 9.0 P= 0.583
Number of patients with hypertension 74 (38%)
a
36 (31%) P= 0.584
Number of patients with treated hypertension 49 (66%) 27 (75%) P= 0.474
Abbreviations: IQR, interquartile range (for non-normally distributed variables); SD, standard deviation (for approximately normally distributed variables).
aOne subject lacked information on hypertension.
bFifteen A𝛽− patients and 7 A𝛽+ subjects did not have APOE genotyping available. Percentages are show over the total number of patients with available
APOEgenotypingperA𝛽 group. Tests:𝜒2-test for categorical variables, t tests for ageandeducation, analysis of covariance (ANCOVA) for all other continuous
variables, controlled for age, sex, years of education and, in case of graymatter (GM) andwhitematter (WM) volume, total intracranial volume.
function composite scores (t = −3.4, P < 0.001) than A𝛽− patients.
APOE genotype was neither associated with age (P = 0.31) nor with
A𝛽 PET status (P= 0.57).
3.2 TBSS analysis of the effect
of age and A𝜷 status onMD
TBSS analysis showed a significant A𝛽 status x age interaction for MD.
In A𝛽+ patients, higher age was associated with a stronger increase
in MD compared to that in A𝛽− patients. The peak interaction effects
of A𝛽 status x age were located predominantly within the posterior
parietal white matter including fiber tracts such as the forceps major
and long-projecting fibers connecting posterior brain regions (Figure 1,
Table 2). The results remained virtually unchanged when excluding
those four patients who scored <1.5 SD below the mean on the com-
posite scores of episodic memory or executive function, suggesting
that the findings were not driven by abnormally low-performing sub-
jects. When using global A𝛽 PET SUVR as a continuous rather than
binarymeasure, the interactioneffect globalA𝛽 PETSUVRxageonMD
remained significant in the same tracts (except for the anterior thala-
mic radiation, Supplementary Figure S1 and Supplementary Table S1),
albeit in amore spatially restrictedmanner.
TBSS analysis of the effect of APOE genotype x age interaction on
MD values did not yield any significant results (data not shown).
3.3 ROI-based analysis of the effect
of age and A𝜷 onMD
When analyzed at the fiber-tract ROI level, A𝛽+ status was associated
numerically with higher age-related increase in MD within multiple
tracts thatwere largely consistentwith the location of significant voxel
clusters of the interaction effect reported in the TBSS analysis (Supple-
mentary Figure S2, Supplementary Table S2). However, the test of the
interaction effects were not statistically significant after Bonferroni
correction. This was probably because MD alterations were observed
only in parts of a tract, so that averaging theMDvalues across all voxels
of a tract diluted the effect and thus reduced statistical power.
Linear regression analysis of the interaction effect of APOE geno-
type x age did not yield significant results for any of the fiber tracts
(data not shown).
3.4 Analysis of the effect of age and A𝜷 onWMH
Probability mapping of WMH for A𝛽− and A𝛽+ groups for different
age decades starting at age 46 years is displayed in Figure 2 (forWMH
in patients 30-46 years of age, see Supplementary Figure S3). In both
groups, WMH occurred predominantly in the periventricular white
matter. Regression analysis showeda significant interactionA𝛽 status x
age on the globalWMHratio (B= 0.30, standard error [SE]= 0.14, 95%
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F IGURE 1 TBSSmap of the interaction effect of age x global A𝛽 PET status (A𝛽− vs A𝛽+) onMDwithin the white matter (WM) skeleton (blue)
in the axial view (upper two rows) and sagittal view (lower two rows). At higher levels of global amyloid PET, age was associated with a stronger
increase inMD than at lower levels of global amyloid PET. No interaction effects were observed in the opposite direction. P-values associated with
the interaction effect are encoded in warm colors (red to yellow); the significance level was P< 0.05 FWE corrected
TABLE 2 Voxel-based analysis: anatomical labels, coordinates inMNI space, and t value of the TBSS-derived peaks of each cluster of the
interaction effects of A𝛽 PET status by age onMD
Tract Lobe/side X Y Z t value
Inferior frontooccipital fasciculus Parietal/L −29 −45 18 4.81
Superior longitudinal fasciculus Frontal/R 36 −15 34 4.41
Superior longitudinal fasciculus Parietal/R 21 −44 47 3.77
Superior longitudinal fasciculus Temporal/R 32 −2 13 3.96
Cingulum Parietal/R 19 −54 36 4.04
Forcepsmajor Parietal 17 −43 10 4.30
Inferior longitudinal fasciculus Parietal/R 27 −42 25 4.04
Abbreviations: L, left, R, right.
confidence interval [CI] = 0.07-0.59, P = 0.026), such that the associ-
ation between higher age and higher global WMH ratio was stronger
in the A𝛽+ compared to the A𝛽− group (Figure 3). To ensure that zero
or very low values of WMH volume did not influence the results, we
repeated the regression analysis with cases ofWMHvolume below the
fifth percentile (n = 25) excluded (B = 0.29, SE = 0.14, 95% CI = 0.02-
0.58, P = 0.037). The interaction effect remained also significant when
controlling for hypertension (full sample: B = 0.33, SE = 0.13, 95%
CI=0.07-0.59,P=0.015),wherehypertensionhadno significant effect
onWMH ratio (data not shown).
4 DISCUSSION
The major results of the current adult life span study in cognitively
normal subjects (30-89 years) showed abnormal global A𝛽 deposi-
tion (global Florbetapir F-18 PET) to be associated with stronger
age-related MD alterations, particularly within the posterior pari-
etal white matter. A𝛽+ status was also associated with stronger age-
related increase in globalWMH volume, independent of hypertension.
Together, these results suggest that A𝛽 deposition is associated with
white matter alterations throughout the adult life span in cognitively
normal subjects.
Increased MD in the posterior parietal white matter included
fiber tracts such as the forceps major, inferior frontooccipital fasci-
culus, and superior longitudinal fasciculus. These fiber tracts connect
among others regions of the default mode network (DMN),47 that
is, a major functional network impaired in both cognitively nor-
mal subjects with elevated A𝛽 levels48,49 and patients with AD
dementia.50 White matter alterations in tracts connecting the DMN
were shown previously to be associated with reduced functional
connectivity in patients with AD,44 suggesting that white matter
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F IGURE 2 WMHprobability maps superimposed onto axial brain slices within the A𝛽− group (upper panel) and A𝛽+ group (lower panel) for
different age groups (columns). The number of subjects per A𝛽 and age group is indicated above the slices
alterations contribute to impairment in key functional networks
in AD.
The posterior parietal spatial distribution of MD alterations
observed in the current study shows a spatial similarity to that pre-
viously found in mild AD51,52 (for review see53), and in subjects with
autosomal dominant AD.13 In autosomal dominant AD, we previously
reported higher MD within the forceps major 10 years before symp-
tom onset, with other major long-projecting fibers tracts such as the
inferior frontooccipital fasciculus, superior longitudinal fasciculus, and
forceps minor affected subsequently.13 Similarly, in the current study,
we observed significant amyloid-relatedMD increase that was located
primarily in temporal and posterior brain regions. It should be noted
that the white matter alterations extended to frontal fiber tracts such
as the anterior thalamic radiation. Alterations in the frontal white mat-
ter, including amongother regions the anterior thalamic radiation, have
been reported previously in late-onset AD.54,55 It is thus possible that
due to the age difference between autosomal dominant Alzheimer’s
disesae compared to late onset AD,13 more frontal white matter alter-
ations are present in late-onset AD. Whether regional differences in
A𝛽 PETcontribute to regionallymatchingdifferences inMDalterations
wasnot possible to address in the current study, given that localA𝛽 PET
values are highly intercorrelated and thus regional A𝛽 PET changes are
difficult to disentangle from global A𝛽 PET changes.
The underlying mechanisms of A𝛽-related MD alterations remain
unclear. One possibility is that the deposition of A𝛽 enhances small
vessel disease, in the form of cerebral amyloid angiopathy (CAA).
White matter damage in AD might thus be related to vascular mech-
anisms, such as hypoperfusion (for reviews see6,56). Cerebrovascular
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F IGURE 3 Regression plot showing the interaction between A𝛽 status x age on globalWMHvolume ratio for the full sample (A) and the subset
of subjects, excluding those falling below the fifth percentile ofWMHvolume (B) to ensure that the results were not driven by zero (or very low)
WMHvolume. The shaded area indicates the standard error
pathology such as CAA occurs in the majority of patients with AD,57
and its prevalence is also increased in cognitively normal subjects
exhibiting neuritic amyloid plaques.58 A𝛽 induces vasoconstriction and
reduces functional hyperemia, as observed inmousemodels of cerebral
A𝛽 deposition.56,59 Furthermore, higher parenchymal A𝛽 may enhance
CAA and associated perfusion alterations.60 Microstructural white
matter alterations becoming visible as WMH have been associated
previously with small vessel disease changes including capillary CAA
and hypoperfusion.21,61 In the current study, we found higher age-
related increase in WMH volume in subjects with abnormal Florbe-
tapir F-18 PET levels compared to those with normal Florbetapir F-18
PET. Consistent with our results, relatively young patients with auto-
somal dominant AD showed an increase in WMH subsequent to amy-
loid deposition,7 suggesting that amyloid pathology may entail white
matter alterations. In humans, arterial spin labeling studies showed
that lower tissue perfusionwas associated not only withWMHvolume
but also DTI alterations in fiber tracts outside the WMH.62 Together,
these results suggest that A𝛽-related small vessel disease constitutes
a potential pathomechanism underlying themicrostructural fiber tract
alterations observed in the current study.
Hypertension is an age-related cerebrovascular risk factor andmay
thus enhance the risk of white matter alterations. In addition, cere-
brovascular disease has been suggested to enhance the development
of AD,63 and thus hypertension may not only be a vascular risk fac-
tor but also a risk factor for enhanced accumulation of A𝛽 in the
brain.18 In our study, the effects of A𝛽 on both MD alterations and
WMH were, however, independent of the hypertension status, sug-
gesting that hypertensive small vessel disease does not account for the
observed effects on white matter. It is still possible that hypertension
enhances the development of A𝛽18 and exacerbates A𝛽-related small
vessel disease,64 but in the current study, hypertension was not the
major determinant. We caution, however, that in the majority of cases
hypertension was treated, and thus any effects of hypertension may
have been attenuated by treatment. Multiple sources may synergisti-
cally contribute to white matter alterations and cognitive decline,65-67
where future studies need to address the causative relationship and
mechanistic pathways between these factors.
For the interpretation of the current study, some caveats should be
considered. Although an increase inMD is commonly thought to reflect
decreased fiber tract integrity, the exact sources of changes in DTI
signal are not well understood.68,69 Changes in MDmay be influenced
by changes in crossing fibers10,68,69 or an increase in extracellular free
water without pronounced alterations of fiber tract structure itself,70
which complicates the attribution of MD differences to underlying
changes in fiber tract integrity. Multishell acquisition protocols and
free water elimination have been developed71-73 to alleviate such
shortcomings; however, this work is ongoing.74 Furthermore, we
focused on MD only, and our results do not necessarily generalize to
other DTI indices such as fractional anisotropy (FA), even though we
found that MD and FA were highly correlated in our data set (data
not shown). Another caveat is that the current study does not include
longitudinal data, which would be instructive to establish the temporal
sequence of age-related development of A𝛽 and white matter changes
during the adult life span.63,75 Reduced perfusion and impaired blood-
brain barrier function havebeenproposed to precede the development
of A𝛽 .1,56,57 Furthermore, small vessel disease may interact with A𝛽
pathology, and thus exacerbate the development of AD pathology.64,76
The current cross-sectional findings cannot disentangle the direction-
ality of the effect that white matter alterations, possibly stemming
from small vessel disease, and A𝛽 pathology may exert on each
other.
Lastly, we note that while our results suggest A𝛽 to be associated
with white matter alterations at higher age, one alternative possibil-
ity is that the association between A𝛽 and white matter alterations
becomes better detectable at higher age, wherewhitematter integrity
is more variable. Biological factors that may enhance the association
between A𝛽 and white matter alterations specifically at higher age
remain still unclear.
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In conclusion, the current study shows that the occurrence of A𝛽
deposition is associated with an age-related increase in white matter
alterations. Our results have clinical implications. Small vessel disease
is treatable, and interventions enhancing vascular health at an early
disease stage may thus alleviate disease progression in patients with
increased levels of A𝛽 .77 Recently developed, clinically applicable neu-
roimaging markers of white matter damage41 could help track white
matter alterations and treatment effects, both in response to vascular
or A𝛽-targeted intervention for secondary prevention.
FUNDING/SUPPORT
The study was supported by the Alzheimer’s Association (to M.E.),
European Research Council PCIG12-GA-2012-334259 (to M.E),
LMUexcellent (to M.E.), National Institute on Aging 5R37AG-006265
(to D.P.) and RC1AG036199 (to D.P.). The PETtracer was provided at
no cost by Avid Radiopharmaceuticals, a wholly owned subsidiary of
Eli Lilly, Inc, which had no role in the design and conduct of the study,
analysis of the data, or manuscript preparation.
CONFLICT OF INTEREST
No conflicts of interest were reported by any author.
ORCID
Michael Ewers https://orcid.org/0000-0001-5231-1714
REFERENCES
1. Zlokovic BV. Neurovascular pathways to neurodegeneration in
Alzheimer’s disease and other disorders. Nat Rev Neurosci. 2011;
12:723-738.
2. Thal DR, Attems J, Ewers M. Spreading of amyloid, tau, and microvas-
cular pathology in Alzheimer’s disease: findings from neuropatho-
logical and neuroimaging studies. J Alzheimers Dis. 2014;42(suppl 4):
S421-S429.
3. JacobsHIL,HeddenT, SchultzAP, et al. Structural tract alterations pre-
dict downstream tau accumulation in amyloid-positive older individu-
als.Nat Neurosci. 2018;21(3):424-431.
4. Mito R, Raffelt D, Dhollander T, et al. Fibre-specific white matter
reductions inAlzheimer’s disease andmild cognitive impairment.Brain.
2018;141(3):888-902.
5. Song SK, Kim JH, Lin SJ, Brendza RP, Holtzman DM. Diffusion tensor
imaging detects age-dependent white matter changes in a transgenic
mouse model with amyloid deposition. Neurobiol Dis. 2004;15:640-
647.
6. Weller RO, BocheD, Nicoll JA.Microvasculature changes and cerebral
amyloid angiopathy in Alzheimer’s disease and their potential impact
on therapy. Acta Neuropathol. 2009;118:87-102.
7. Lee S, Viqar F, ZimmermanME, et al.Whitematter hyperintensities are
a core feature of Alzheimer’s disease: evidence from the dominantly
inherited Alzheimer network. Ann Neurol. 2016;79:929-939.
8. Medina D, DeToledo-Morrell L, Urresta F, et al. White matter changes
in mild cognitive impairment and AD: a diffusion tensor imaging study.
Neurobiol Aging. 2006;27:663-672.
9. Sexton CE, Kalu UG, Filippini N, Mackay CE, Ebmeier KP. A meta-
analysis of diffusion tensor imaging in mild cognitive impairment and
Alzheimer’s disease.Neurobiol Aging. 2011;32:2322.e5-18.
10. Douaud G, Jbabdi S, Behrens TE, et al. DTI measures in crossing-fibre
areas: increased diffusion anisotropy reveals early white matter alter-
ation in MCI and mild Alzheimer’s disease. Neuroimage. 2011;55:880-
890.
11. Caso F, Agosta F, Filippi M. Insights into white matter damage in
Alzheimer’s disease: from postmortem to in vivo diffusion tensor MRI
studies.Neurodegener Dis. 2016;16:26-33.
12. Bendlin BB, Carlsson CM, Johnson SC, et al. CSF T-Tau/Abeta42
predicts white matter microstructure in healthy adults at risk for
Alzheimer’s disease. PLoS One. 2012;7:e37720.
13. AraqueCaballeroMA, Suarez-CalvetM,DueringM, et al.Whitematter
diffusion alterations precede symptom onset in autosomal dominant
Alzheimer’s disease. Brain. 2018;141:3065-3080.
14. Sachdev PS, Zhuang L, BraidyN,WenW. Is Alzheimer’s a disease of the
whitematter?. Curr Opin Psychiatry. 2013;26:244-251.
15. Oxtoby NP, Young AL, Cash DM, et al. Data-driven models of
dominantly-inherited Alzheimer’s disease progression. Brain.
2018;141:1529-1544.
16. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker
changes in dominantly inherited Alzheimer’s disease. N Engl J Med.
2012;367:795-804.
17. JansenWJ,OssenkoppeleR,KnolDL, et al. Prevalenceof cerebral amy-
loid pathology in persons without dementia: a meta-analysis. JAMA.
2015;313:1924-1938.
18. Rodrigue KM, Rieck JR, Kennedy KM, DevousMD, Sr, Diaz-Arrastia R,
ParkDC.Risk factors for beta-amyloid deposition in healthy aging: vas-
cular and genetic effects. JAMANeurol. 2013;70:600-606.
19. Mann DMA, Davidson YS, Robinson AC, et al. Patterns and sever-
ity of vascular amyloid in Alzheimer’s disease associated with dupli-
cations and missense mutations in APP gene, Down syndrome
and sporadic Alzheimer’s disease. Acta Neuropathol. 2018;136(4):
569-587.
20. Paradise MB, Shepherd CE, Wen W, Sachdev PS. Neuroimaging and
neuropathology indices of cerebrovascular disease burden: a system-
atic review.Neurology. 2018;91:310-320.
21. Charidimou A, Martinez-Ramirez S, Reijmer YD, et al. Total magnetic
resonance imaging burden of small vessel disease in cerebral amyloid
angiopathy: an imaging-pathologic study of concept validation. JAMA
Neurol. 2016;73:994-1001.
22. van Veluw SJ, Lauer A, Charidimou A, et al. Evolution of DWI lesions
in cerebral amyloid angiopathy: evidence for ischemia. Neurology.
2017;89:2136-2142.
23. Lebel C, GeeM, Camicioli R,WielerM,MartinW, Beaulieu C. Diffusion
tensor imaging of white matter tract evolution over the lifespan. Neu-
roimage. 2012;60:340-352.
24. Kochunov P,WilliamsonDE, Lancaster J, et al. Fractional anisotropy of
water diffusion in cerebral white matter across the lifespan. Neurobiol
Aging. 2012;33:9-20.
25. Hasan KM, Iftikhar A, Kamali A, et al. Development and aging of the
healthy human brain uncinate fasciculus across the lifespan using dif-
fusion tensor tractography. Brain Res. 2009;1276:67-76.
26. Dean DC, 3rd, Hurley SA, Kecskemeti SR, et al. Association of amy-
loid pathology with myelin alteration in preclinical Alzheimer disease.
JAMANeurol. 2017;74:41-49.
27. Song Z, Farrell ME, Chen X, Park DC. Longitudinal accrual of neo-
cortical amyloid burden is associated with microstructural changes
of the fornix in cognitively normal adults. Neurobiol Aging. 2018;68:
114-122.
28. Racine AM, Merluzzi AP, Adluru N, et al. Association of longitudinal
white matter degeneration and cerebrospinal fluid biomarkers of neu-
rodegeneration, inflammation and Alzheimer’s disease in late-middle-
aged adults. Brain Imaging Behav. 2019;13(1):41-52.
29. Gold BT, Zhu Z, Brown CA, et al. White matter integrity is associ-
ated with cerebrospinal fluid markers of Alzheimer’s disease in normal
adults.Neurobiol Aging. 2014;35:2263-2271.
30. Chao LL, Decarli C, Kriger S, et al. Associations between white matter
hyperintensities and beta amyloid on integrity of projection, associa-
tion, and limbic fiber tracts measured with diffusion tensor MRI. PLoS
One. 2013;8:e65175.
660 CABALLERO ET AL.
31. Rieckmann A, Van Dijk KR, Sperling RA, Johnson KA, Buckner RL,
Hedden T. Accelerated decline in white matter integrity in clinically
normal individuals at risk for Alzheimer’s disease. Neurobiol Aging.
2016;42:177-188.
32. Racine AM, Adluru N, Alexander AL, et al. Associations between white
matter microstructure and amyloid burden in preclinical Alzheimer’s
disease: a multimodal imaging investigation. NeuroImage Clinical.
2014;4:604-614.
33. Li X, Li TQ, Andreasen N, Wiberg MK, Westman E, Wahlund LO. The
association between biomarkers in cerebrospinal fluid and structural
changes in the brain in patients with Alzheimer’s disease. J Intern Med.
2014;275:418-427.
34. Song Z, McDonough IM, Liu P, Lu H, Park DC. Cortical amyloid burden
and age moderate hippocampal activity in cognitively-normal adults.
NeuroImage Clinical. 2016;12:78-84.
35. Rodrigue KM, Kennedy KM, Devous MD, et al. 𝛽-Amyloid burden in
healthy aging.Neurology. 2012;78:387-395.
36. BischofGN, Jessen F, FliessbachK, et al. Impact of tau and amyloid bur-
den on glucose metabolism in Alzheimer’s disease. Ann Clin Transl Neu-
rol. 2016;3:934-939.
37. Leemans A, Jeurissen B, Sijbers J, Jones D, ExploreDTI: a graphical tool-
box for processing, analyzing, and visualizing diffusion MRI data. Proceed-
ings of the 17th Annual Meeting of International Society for Magnetic
Resonance inMedicine Hawaii, USA. 2009, pp. 3536.
38. Leemans A, Jones DK. The B-matrix must be rotated when cor-
recting for subject motion in DTI data. Magn Reson Med. 2009;61:
1336-1349.
39. Irfanoglu MO, Walker L, Sarlls J, Marenco S, Pierpaoli C. Effects of
image distortions originating from susceptibility variations and con-
comitant fields on diffusion MRI tractography results. Neuroimage.
2012;61:275-288.
40. Smith SM, Jenkinson M, Johansen-Berg H, et al. Tract-based spatial
statistics: voxelwise analysis of multi-subject diffusion data. Neuroim-
age. 2006;31:1487-1505.
41. Baykara E, Gesierich B, AdamR, et al. A novel imagingmarker for small
vessel disease based on skeletonization of white matter tracts and dif-
fusion histograms. Ann Neurol. 2016;80:581-592.
42. Hua K, Zhang J, Wakana S, et al. Tract probability maps in stereotaxic
spaces: analyses of white matter anatomy and tract-specific quantifi-
cation.Neuroimage. 2008;39:336-347.
43. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for
research into small vessel disease and its contribution to ageing and
neurodegeneration. Lancet Neurol. 2013;12:822-838.
44. Taylor AN, Kambeitz-Ilankovic L, Gesierich B, et al. Tract-specific white
matter hyperintensities disrupt neural network function inAlzheimer’s
disease. Alzheimers Dement. 2017;13:225-235.
45. Winkler AM, Ridgway GR, Webster MA, Smith SM, Nichols TE.
Permutation inference for the general linear model. Neuroimage.
2014;92:381-397.
46. Venables WN, Ripley BD. Modern Applied Statistics With S. 4th ed.
New York City: Springer; 2002.
47. Greicius MD, Supekar K, Menon V, Dougherty RF. Resting-state func-
tional connectivity reflects structural connectivity in the default mode
network. Cereb Cortex. 2009;19:72-78.
48. Wang L, BrierMR, Snyder AZ, et al. Cerebrospinal fluid Abeta42, phos-
phorylated Tau181, and resting-state functional connectivity. JAMA
Neurol. 2013;70:1242-1248.
49. Elman JA,MadisonCM, Baker SL, et al. Effects of beta-amyloid on rest-
ing state functional connectivity within and between networks reflect
known patterns of regional vulnerability. Cereb Cortex. 2016;26:695-
707.
50. Badhwar A, Tam A, Dansereau C, Orban P, Hoffstaedter F, Bel-
lec P. Resting-state network dysfunction in Alzheimer’s disease: a
systematic review and meta-analysis. Alzheimers Dement. 2017;8:
73-85.
51. Acosta-Cabronero J, Alley S, Williams GB, Pengas G, Nestor PJ. Dif-
fusion tensor metrics as biomarkers in Alzheimer’s disease. PLoS One.
2012;7:e49072.
52. Acosta-Cabronero J, Williams GB, Pengas G, Nestor PJ. Absolute
diffusivities define the landscape of white matter degeneration in
Alzheimer’s disease. Brain. 2010;133:529-539.
53. Acosta-Cabronero J, Nestor PJ. Diffusion tensor imaging in
Alzheimer’s disease: insights into the limbic-diencephalic network
andmethodological considerations. Front Aging Neurosci. 2014;6:266.
54. Niida A, Niida R, Kuniyoshi K, Motomura M, Uechi A. Usefulness of
visual evaluation of the anterior thalamic radiation by diffusion ten-
sor tractography for differentiating between Alzheimer’s disease and
elderly major depressive disorder patients. Int J Gen Med. 2013;6:189-
200.
55. Tu MC, Lo CP, Huang CF, et al. Effectiveness of diffusion tensor
imaging in differentiating early-stage subcortical ischemic vascular
disease, Alzheimer’s disease and normal ageing. PLoS One. 2017;12:
e0175143.
56. KislerK,NelsonAR,MontagneA,ZlokovicBV.Cerebral blood flowreg-
ulation and neurovascular dysfunction in Alzheimer disease. Nat Rev
Neurosci. 2017;18:419-434.
57. Iadecola C. The pathobiology of vascular dementia. Neuron.
2013;80:844-866.
58. Jicha GA, Abner EL, Schmitt FA, et al. Preclinical ADWorkgroup stag-
ing: pathological correlates and potential challenges. Neurobiol Aging.
2012;33:622.e1-e16.
59. Niwa K, Younkin L, Ebeling C, et al. Abeta 1-40-related reduction in
functional hyperemia in mouse neocortex during somatosensory acti-
vation. PNAS. 2000;97:9735-9740.
60. Maier FC, Wehrl HF, Schmid AM, et al. Longitudinal PET-MRI reveals
beta-amyloid deposition and rCBF dynamics and connects vascular
amyloidosis to quantitative loss of perfusion. Nat Med. 2014;20:1485-
1492.
61. Shi Y, ThrippletonMJ,Makin SD, et al. Cerebral blood flow in small ves-
sel disease: a systematic review and meta-analysis. J Cereb Blood Flow
Metab. 2016;36:1653-1667.
62. PromjunyakulN, LahnaD, Kaye JA, et al. Characterizing thewhitemat-
ter hyperintensity penumbra with cerebral blood flow measures. Neu-
roImage Clinical. 2015;8:224-229.
63. Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Perez JM, Evans
AC, Alzheimer’sDiseaseNeuroimaging Initiative. Early role of vascular
dysregulation on late-onset Alzheimer’s disease based on multifacto-
rial data-driven analysis.Nat Commun. 2016;7:11934.
64. Faraco G, Park L, Zhou P, et al. Hypertension enhances Abeta-
induced neurovascular dysfunction, promotes beta-secretase activ-
ity, and leads to amyloidogenic processing of APP. J Cereb Blood Flow
Metab. 2016;36:241-252.
65. Rabin JS, Schultz AP, Hedden T, et al. Interactive associations of vascu-
lar risk andbeta-amyloidburdenwith cognitivedecline in clinically nor-
mal elderly individuals: findings from the Harvard Aging Brain Study.
JAMANeurol. 2018;75:1124-1131.
66. Lee MJ, Seo SW, Na DL, et al. Synergistic effects of ischemia and
beta-amyloid burden on cognitive decline in patients with subcor-
tical vascular mild cognitive impairment. JAMA psychiatry. 2014;71:
412-422.
67. Vemuri P, Lesnick TG, Przybelski SA, et al. Vascular and amyloid
pathologies are independent predictors of cognitive decline in normal
elderly. Brain. 2015;138:761-771.
68. Jeurissen B, Leemans A, Tournier JD, Jones DK, Sijbers J. Investigat-
ing the prevalence of complex fiber configurations in white matter
tissue with diffusion magnetic resonance imaging. Hum Brain Mapp.
2013;34:2747-2766.
69. Jones DK, Knosche TR, Turner R. White matter integrity, fiber count,
and other fallacies: the do’s and don’ts of diffusion MRI. Neuroimage.
2013;73:239-254.
CABALLERO ET AL. 661
70. Pasternak O, Sochen N, Gur Y, Intrator N, Assaf Y. Free water elimina-
tion and mapping from diffusion MRI.Magn Reson Med. 2009;62:717-
730.
71. Zhang H, Schneider T, Wheeler-Kingshott CA, Alexander DC. NODDI:
practical in vivo neurite orientation dispersion and density imaging of
the human brain.Neuroimage. 2012;61:1000-1016.
72. Duering M, Finsterwalder S, Baykara E, et al. Free water determines
diffusion alterations and clinical status in cerebral small vessel disease.
Alzheimers Dement. 2018.
73. Maier-Hein KH,Westin CF, ShentonME, et al. Widespread white mat-
ter degeneration preceding the onset of dementia. Alzheimers Dement.
2015;11:485-493.e2.
74. HoyAR, KoayCG, Kecskemeti SR, AlexanderAL.Optimization of a free
water elimination two-compartment model for diffusion tensor imag-
ing.Neuroimage. 2014;103:323-333.
75. Lo RY, Jagust WJ, Alzheimer’s Disease Neuroimaging Initiative. Vas-
cular burden andAlzheimer disease pathologic progression.Neurology.
2012;79:1349-1355.
76. Iadecola C, Zhang F, Niwa K, et al. SOD1 rescues cerebral endothe-
lial dysfunction in mice overexpressing amyloid precursor protein.Nat
Neurosci. 1999;2:157-161.
77. Iturria-Medina Y, Carbonell FM, Sotero RC, Chouinard-Decorte F,
Evans AC, Alzheimer’s Disease Neuroimaging Initiative. Multifactorial
causal model of brain (dis)organization and therapeutic intervention:
application to Alzheimer’s disease.Neuroimage. 2017;152:60-77.
78. OtsuN. A threshold selectionmethod from gray-level histograms. IEEE
Trans Syst Man Cybern. 1979;9:62-66.
79. Ashburner J. A fast diffeomorphic image registration algorithm. Neu-
roimage. 2007;38:95-113.
SUPPORTING INFORMATION
Additional supporting informationmay be found online in the Support-
ing Information section at the end of the article.
How to cite this article: CaballeroMÁA, Song Z, Rubinski A,
et al. Age-dependent amyloid deposition is associated with
white matter alterations in cognitively normal adults during
the adult life span. Alzheimer’s Dement. 2020;16:651–661.
https://doi.org/10.1002/alz.12062
